
Opinion|Videos|October 13, 2023
Evolving Treatment Strategies in HER2-Positive Early Breast Cancer
Author(s)Sandra M. Swain, MD, FACP, FASCO
Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5












































